At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
In 2017, RBV Capital acquired an equity stake in an innovative UK-based company developing an asset for treating symptoms of multiple sclerosis
Image Analysis Group (“IAG”).today announced a partnership in the field of ulcerative colitis (UC) histopathological image analysis with Takeda Pharmaceutical Company Limited (“Takeda”).
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
